Pascal Soriot, AstraZeneca CEO (Raphael Lafargue/Abaca/Sipa USA; Sipa via AP Images)
May 25, 2021 08:47 AM EDT
Deals
Pharma

UK be­gins in­quiry in­to As­traZeneca's $39B buy­out of Alex­ion

Zachary Brennan

Senior Editor

The UK’s Com­pe­ti­tion and Mar­kets Au­thor­i­ty opened an in­quiry on Tues­day in­to As­traZeneca’s pro­posed $39 bil­lion ac­qui­si­tion of Alex­ion.

By Ju­ly 21, the CMA …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Trump 2.0 blog: Way­back Ma­chine is in­suf­fi­cient for US health da­ta, judge says

Tra­vere plans to seek ex­pand­ed la­bel for kid­ney drug de­spite failed tri­al

Pfiz­er’s prostate can­cer da­ta leak shows promis­ing re­sults in ear­ly-stage study

Bio­haven lands pri­or­i­ty re­view on sec­ond-chance ap­pli­ca­tion for neu­rode­gen­er­a­tive drug

What will phar­ma's share buy­back shop­ping spree mean for M&A?

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times